RxDoctor Payments Data

Casey Mraz, MD

Family Medicine · Midland, TXNPI 1659728855

Payments from drug & device makers

$2,783in general payments, 2019–2025

Across 164 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$719
  • Novo Nordisk$309
  • Pfizer$302
  • AstraZeneca$293
  • GSK$244
  • Boehringer Ingelheim$161
  • plus $756 from 14 others

What the payments were for

  • Food & beverage$2,783100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,783 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$28,615
Medicare patients
117
Services billed
344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$103,269
MounjaroTirzepatide66$75,373
JardianceEmpagliflozin30$41,530
RybelsusSemaglutide11$27,346
EliquisApixaban22$22,969
VascepaIcosapent Ethyl12$5,986
Levothyroxine Sodium161$1,950
Bupropion XlBupropion Hcl55$1,774
Rosuvastatin Calcium112$1,467
Gabapentin122$1,246
Venlafaxine Hcl ErVenlafaxine Hcl17$1,177
Pantoprazole Sodium77$1,138
Celecoxib11$1,039
Escitalopram Oxalate80$1,036
Olmesartan Medoxomil49$980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$309$130,61595 claims
Lilly USA, LLCMounjaro$719$75,37366 claims
Boehringer IngelheimJardiance$161$41,53030 claims
PfizerEliquis$302$22,96922 claims
AbbVieArmour Thyroid, Synthroid$42$1,66824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Midland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →